Skip to NavigationSkip to content

Neurodegenerative market to be worth $45 billion by 2022

Published on 12/12/16 at 10:46am

Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which is projected to rise in value to be worth $45 billion by 2022, up from $27.2 billion last year, according to new data form GBI Research.

The primary driving factor given for this growth is the expected approval of a number of pipeline products between 2018 and 2022 such as Roche’s ocrelizumab, which is expected to pull the company ahead of its rivals in the space.

“There is a large pharmaceutical pipeline for neurodegenerative disorders, consisting of approximately 1494 products in active development,” GBI Research analyst Qaisrah Khalid explained: “The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics, or repositioned from other indications – most of which are at Phase I. This indicates progress in terms of different molecules being developed as therapeutic agents within the neurodegenerative pipeline.”

Khalid continued: “The revenue for the highest-selling product within the MS market – Copaxone (glatiramer acetate), marketed by Teva – is expected to decrease substantially following its 2014 patent expiry, from just over $4 billion in 2015 to $2.5 billion by 2022, owing to competition from generics, such as Glatopa. Declining revenues from this and other drugs will lead to a significant drop in the neurodegenerative disorder market share for Teva.”

Biogen, Novartis and Sanofi are expected to maintain their hold on the market despite impending patent expiries, the report added.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches